The effect of treating with anti-interleukin-1 receptor antibody on the course of experimental murine cutaneous leishmaniasis.
To assess the role of interleukin-1 (IL-1) in cutaneous leishmaniasis, Leishmania major-infected mice were treated with an anti-IL-1 receptor monoclonal antibody, LA-15.6. MoAb LA-15.6 prevents binding of IL-1 to both the T cell and B cell/macrophage forms of the IL-1 receptor. We found that treating with LA 15.6 inhibited the development of cutaneous lesions of L. major in both genetically-susceptible and resistant mice. Interestingly, this treatment had little or no effect on parasite numbers in the lesions or on the cytokines (interferon-gamma, interleukin-4) that the animals produced in response to infection with the parasite. These results suggest that although IL-1 plays a detrimental role in cutaneous leishmaniasis, it does not mediate this effect by altering the parasite-specific T cell response.
Theodos
C M
CM
Department of Tropical Public Health, Harvard School of Public Health, Boston, MA 02115.
Shankar
A
A
Glasebrook
A L
AL
Roeder
W D
WD
Titus
R G
RG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D007375:Interleukin-1; D018320:Leishmania major; D016773:Leishmaniasis, Cutaneous / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018512:Parasitemia / Q000188:drug therapy / Q000276:immunology; D017472:Receptors, Interleukin-1 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007375:Interleukin-1; D017472:Receptors, Interleukin-1